TISSUE THERAPIES



Tissue Therapies Ltd

Annual General Meeting

27 November 2008

Lead product VitroGro®: designed to provide simple, cost effective, new treatments for diabetic , venous & pressure ulcers

TISSUE THERAPIES





Company Highlights

1. Lead product VitroGro®: designed to deliver new, efficient, cost effective, growth factor based treatment for diabetic, venous & pressure ulcers
2. US$4 billion world wide market, 11 – 15% compound annual growth rate
3. More than 1 million amputations per annum due to diabetes
4. Diabetes pandemic is one driver of market growth
5. Current treatments are expensive and often don't work
6. More than 6 years of VitroGro® published data including live human skin and preclinical studies shows quick wound healing with reduced scarring
7. Device classification = easy, short clinical trial: continuous disclosure & final results within 6 months of start
8. Human trial results catalyst for detailed commercial negotiations with interested international companies
9. Regulatory approval is not a prerequisite for a strategic commercial partnership





Preclinical Results: VitroGro®
Treatment of Deep Excisional Wounds

Day 0



Day 13 Control



Day 13 VitroGro®



TISSUE THERAPIES





Preclinical Results: VitroGro®
Treatment of Deep Excisional Wounds

VitroGro® produced exceptional wound healing in only 13 days that:

- is scarless
- is almost indistinguishable from uninjured surrounding skin
- restores:
  - normal skin pigmentation
  - normal hair distribution and direction





Key Financial Data

1. Formed September 2002
2. ASX listing 19 March 2004
3. Current Issued Capital: 44.891 million shares
4. Current share price AUD $0.10
5. Market Capitalisation approx. AUD$4.5 million
6. Cash end Oct. AUD $860,000
7. Burn rate approx. AUD $160,000 per month





Tissue Therapies Board & Advisors

1. Chairman: Mr Roger Clarke, ABN Amro Morgans
2. Directors:
   - Mr Gregory Baynton, Managing Director Orbit Capital
   - Mr Donald Home, CEO Incitive Ltd, formerly Agenix, Australian Genome Diagnostics, Abbott Laboratories (Aust. & USA)
   - Prof. David Gardiner, Senior Deputy VC, Prof. of Law, QUT
   - Dr Steven Mercer, CEO Tissue Therapies, formerly Mercy Tissue Engineering, Smith & Nephew Surgical, IBM Health Industries
3. Advisors:
   - Prof. Zee Upton, Chief Scientific Advisor
   - Prof. Keith Harding, Cardiff University
   - Prof. Rob Baxter, Kolling Institute, University of Sydney (RNSH)





What is VitroGro®

1. A novel protein formulation for enhancing cell growth, cell migration and protein production = wound healing
2. VitroGro® combines active regions of naturally occurring growth factors, binding and activation proteins into a single protein
3. VitroGro® accelerates human skin cell growth and migration by using normal tissue healing mechanisms
4. Only very low doses of VitroGro® required (nanograms per square cm of wound), once or twice per week





Key Benefits of VitroGro®

Designed to deliver cost effective, predictable wound healing with very low doses.
Potential for new wound healing treatments for diabetic, venous and pressure ulcers, that will be more cost effective than existing treatments.
Retains wound healing activity in presence of chronic wound fluid.
Can be freeze dried for easy, cheap storage, transport and incorporation into wound dressings / treatments.
Retains wound healing activity after gamma irradiation; important for quick, cheap incorporation into wound dressings that are routinely sterilised with gamma irradiation at end of manufacture.
Promotes effective wound healing in human skin cells biopsied from the edge of chronic diabetic ulcers, in the presence of elevated glucose.
Allows creation of live human skin in the laboratory; proof of the power and versatility of VitroGro® and an exceptional research tool.





TARGET WOUND CARE MARKET



Global Market

- 194 million diabetics today → 333 million in 2025
- >1 million amputations per annum = 1 every 30 seconds
- 70% of all lower limb amputations due to non-healing diabetic ulcers





Human Trials of VitroGro®

1. Clinical trial of VitroGro® in Perth, started August 2008: Prof. Michael Stacey: 1st 4 patient results released
2. Clinical trial of VitroGro® in Toronto, Canada started Monday 17 Nov. 2008: Prof. Gary Sibbald
3. Both human trials:
   - short with progressive release of results
   - final results within 6 months of first patient treatment
   - are complementary:
     Perth - venous ulcers
     Toronto – venous, diabetic & pressure ulcers
4. Positive human trial data catalyst for formal partnership negotiations
5. Regulatory approval is not a prerequisite for a strategic commercial partnership





VitroGro® Risk Profile

- 100% pure recombinant human protein
- proteins normally present in human serum & tissues
- produced to GMP standard
- only nanogram doses per sq cm
- local (topical) treatment only
- restores normal protein complexes present before the injury / disease state occurred

Health Canada Device Classification

TISSUE THERAPIES





When is a Clinical Trial Lower Risk than Usual?

- More than 6 years of proven / published VitroGro® preclinical results with human cells and tissues – predominantly human skin
- VitroGro® data includes live human cells: skin, breast, cornea, fibroblasts & stem cells
- Creation of live human skin on lab bench:
  - Human skin structure
  - Normal response to injury
  - Healing accelerated by VitroGro®
- Expert, experienced clinical trials team & CTM: multiple prior successes including Acticoat™ (Smith & Nephew)
- Exceptional results from 1st 4 patients





Market Segment Opportunity Estimates



Business Strategy

1. Complete human trials and announce results in early 2009 (Fremantle), first half 2009 (Toronto), within 6 months of first patient treatment
2. Use positive human trial data in formal partnership negotiations
3. Proceed with contract, exclusive, large scale, GMP manufacturing of VitroGro®
4. Repeat a small clinical trial of large scale VitroGro® using current human trial protocol and apply for regulatory approval in Canada & mutual recognition territories
5. Leverage world wide sales & distribution of an appropriate commercial partner
6. Wound care revenue expected to start 1st half calendar 2011, plus cell media revenue from Invitrogen Corp. 1 year earlier





Original VitroGro®
New Formulation VitroGro®

Clinical Human Trials

Q3 2008 – Q1 2009

Negotiation with Health/Wound Care Companies

Q4 2008 – Q4 2009

Scale up Manufacture

Q1 – Q3 2009

Health Canada and Ethics Approval for Clinical Human Trial

Q3 – Q4 2009

Clinical Human Trial New Formulation VitroGro®

Q1 – Q2 2010

Regulatory Approval New Formulation VitroGro®

Q3 – Q4 2010

TISSUE THERAPIES





Chronic Wound Care: VitroGro® Competition

- Conventional dressings incl. compression
- Foams
- Hydrocolloids
- Hydrogels
- Alginates
- Cultured cells Dermagraft™ S&N
- Vacuum dressings eg. KCl
- Growth factor dressings eg. fibroblasts, Regranex™ (PDGF:J&J)
- Amputation

Alevyn™ foam dressing: Smith & Nephew



Transcyte™ neonatal fibroblast dressing: Smith & Nephew





Future VitroGro® Product Range

- Diabetic, Venous & Pressure Ulcers
  - accelerated healing, dressing change every 3-4 days
  - correction of wound tissue pathology and physiologic delivery of appropriate growth factor activators
- Burns Paediatric & Adult
  - accelerated scarless healing
- Surgical Applications
  - wound closure for at-risk patients eg. obese, diabetic, smoker, advanced vascular disease
  - other surgical applications eg. stoma care
- Cascade: Specialist Unit to Retail
  - specialist unit – general hospital – outpatient – GP – pharmacy – retail: dressings, creams, lotions, product range for burns, chronic wounds, acute sunburn etc.





Future Product Pipeline

- Growth of Stem Cells
  - VitroGro® completely synthetic replacement for animal/human proteins in cell growth media - more than 20 generations of 4 stem cell lines
  - In combination with collaborator's technology, also allows removal of feeder cells – more than 40 generations, 2 stem cell lines
  - No differentiation ie. no loss of pluripotential nature of stem cells
- Protease Inhibitor Bandage
  - Removes inhibitory enzymes that delay healing
  - Combines VitroGro® with already approved pharmaceutical
- Scar Remediation (First Right of Refusal for Commercialisation)
  - Specific silicon molecules discovered to reduce skin cell formation of scar tissue
  - Developed by cell biologists and polymer chemists at QUT
- Bioactive Bandage (First Right of Refusal for Commercialisation)
  - Australian Research Council collaboration between QUT, Univ. of Qld and Tissue Therapies
  - Combines nano-beads with VitroGro® for sustained release wound dressings





Day 0

Day 24


Change in wound area
Wound Area (cm²)
5
4
3
2
1
0
VitroGro® treatment ceased on day 15
Initial
Day 7
Day 15
Day 24